16May 2021
LITAF acts as a novel regulator for pathological cardiac hypertrophy

LITAF acts as a novel regulator for pathological cardiac hypertrophy

Pathological hypertrophy generally progresses to heart failure. Exploring effective and promising therapeutic targets might lead to progress in preventing its detrimental outcomes. Our current knowledge about lipopolysaccharide-induced tumor necrosis factor-α factor (LITAF) is mainly limited to regulate inflammation. However, the role of LITAF in other settings are not that relevant to inflammation, such as cardiac remodeling and heart failure...

  • #cardiology

Like

Save

Share